From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy
Human Reproduction · 2026
DOI: 10.1093/humrep/deag027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, 2026. Verfasst von Flor Pasturino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Philosophy and Ethics Group, Department of Industrial Engineering & Innovation Sciences, Eindhoven University of Technology, Eindhoven, The Netherlan…. Hauptthemen laut MEDLINE: Infertility, Female, Mitochondria, Mitochondrial Diseases, Mitochondrial Replacement Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Maternal spindle transfer (MST) and pronuclear transfer (PNT) raise a number of important ethical and regulatory issues. These IVF procedures that transfer nuclear DNA to enucleated oocytes or zygotes aim to prevent transmitting mitochondrial disease by female carriers of mitochondrial DNA (mtDNA) mutations and enable them to have healthy genetically related children. MST/PNT might also prove effective in treating oocyte-related infertility, but are not permitted in the UK and Australia, unlike MST/PNT for mtDNA disorders. The paper discusses the regulation of MST/PNT for both applications in relation to their risks and efficacy, highlighting the scarcity of clinical data. Based on risk reduction, it has even been proposed to treat oocyte-related infertility first before moving to mtDNA disorders. We argue that a prohibition of MST/PNT for infertility is not justified, neither should it initially be applied only for infertility because of the little evidence yet available regarding its efficacy and potential risks. We propose a staged approach to identify MST/PNT-treatable causes of oocyte-related infertility first, followed by a preclinical study and clinical trial and, if positive, wider application. Importantly, we call for transparency in publishing regular trial results, deeper ethical reflection, and more consistent policies that consider comparable uncertainties in mtDNA disorders and oocyte-related infertility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Philosophy and Ethics Group, Department of Industrial Engineering & Innovation Sciences, Eindhoven University of Technology, Eindhoven, The Netherlands.
- Department of Health, Ethics and Society, Research Institutes GROW and CAPHRI, Maastricht University, Maastricht, The Netherlands.
- Centre for Reproduction Research, De Montfort University, Leicester, UK.
- Department of Translational Genomics, Research Institutes MHeNS and GROW, Maastricht University, Maastricht, The Netherlands.
ORCID-Profile: Flor Pasturino, Guido M W R De Wert, Cathy Herbrand, Hubert J M Smeets
Zitieren
APA
Pasturino, F., De Wert, G. M. W. R., Herbrand, C., & Smeets, H. J. M. (2026). From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy. Human Reproduction. https://doi.org/10.1093/humrep/deag027
Vancouver
Pasturino F, De Wert GMWR, Herbrand C, Smeets HJM. From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy. Human Reproduction. 2026. doi:10.1093/humrep/deag027
BibTeX
@article{Pasturino2026,
author = {Pasturino, Flor and De Wert, Guido M W R and Herbrand, Cathy and Smeets, Hubert J M},
title = {From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy},
journal = {Human Reproduction},
year = {2026},
doi = {10.1093/humrep/deag027}
}
EUVIMED